• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MJFF launches $14M Edmond J. Safra Core programs for Parkinson’s research

MJFF launches $14M Edmond J. Safra Core programs for Parkinson’s research

June 22, 2012
CenterWatch Staff

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has officially opened its Therapeutic Pipeline Program, a newly created funding mechanism that invites research proposals from industry and academic investigators to drive pre-clinical and clinical Parkinson's disease (PD) drug development.

MJFF has committed up to $14 million in funding toward three research programs, which include the Therapeutic Pipeline Program, Rapid Response Innovation Awards and Target Validation.

The Therapeutic Pipeline Program integrates three previous MJFF funding opportunities—the Therapeutics Development Initiative, Clinical Intervention Awards and Repositioning Drugs for PD—into a single streamlined initiative. The Foundation has extended the initial application acceptance period in order to allow research applicants to develop a comprehensive, multi-phased plan for their promising Parkinson's therapeutics in development.

"We've updated our annual funding initiatives to streamline processes and support our goal of bringing new treatments to market faster," said Sonal Das, Ph.D., associate director of research programs at MJFF. "We're aiming to cut even more red tape out of our application procedures by allowing successful projects to continue through multiple phases of the drug development process without needing to pause and reapply for funding at every stage of the pipeline."

Das emphasized that applicants must present both a therapeutic strategy with clear potential for PD and a well-defined plan for driving their strategy through pre-clinical testing and into the clinic. In making funding decisions, the Foundation prioritizes research toward critically needed disease-modifying treatments (those that can protect or restore the degenerating and/or dysfunctional neurons affected in PD), or toward treatments with potential to significantly ease the disabling motor and non-motor symptoms of the disease.

The Therapeutic Pipeline Program is part of the Edmond J. Safra Core Programs for PD Research, the Foundation's annual funding initiatives that serve to identify roadblocks along the therapeutic development pipeline, speeding novel treatments for the disease toward pharmacy shelves. Established in 2008 in honor of the late well-known international banker and philanthropist, the Edmond J. Safra Core Programs for PD Research also include Rapid Response Innovation Awards, focused on breakthrough ideas, and Target Validation, which supports testing of biological targets with potential to become the new PD drugs of the future.

Target Validation and Therapeutic Pipeline Program initial applications are due in September, with funding anticipated early in 2013. Rapid Response Innovation Awards proposals are accepted on a rolling basis with funding decisions made within six weeks of submission.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing